Zanubrutinib could inhibit homing of CLL cells through downregulating homing receptors such as CXCR5 [18], and effectively disrupt AKT/mTOR signaling and NF-κB function, leading to MCL-cell apoptosis [19]. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.